For the quarter ending 2026-01-31.
| Income Statement | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 |
|---|---|---|---|---|
| Revenue | - | - | 0 | - |
| Research and development expenses (including non-cash stock-based compensation expenses of 338 and 397, respectively) | 1,102 | 1,506* | 1,055 | 1,322 |
| General and administrative expenses (including non-cash stock-based compensation expenses of 458 and 658, respectively) | 1,614 | 2,037* | 1,381 | 1,681 |
| Total operating costs and expenses | 2,716 | 3,542 | 2,436 | 3,003 |
| Loss from operations | -2,716 | -3,542* | -2,436 | -3,003 |
| Interest income | 131 | 154* | 156 | 190 |
| Net loss | -2,585 | -3,388* | -2,280 | -2,813 |
| Less net loss attributable to noncontrolling interest | -20 | -33* | -22 | -23 |
| Net loss attributable to common shareholders | -2,565 | -3,355 | -2,258 | -2,790 |
| Basic EPS | -0.08 | 0.052 | -0.07 | -0.09 |
| Diluted EPS | -0.08 | 0.052 | -0.07 | -0.09 |
| Basic Average Shares | 33,240,000 | -64,580,638 | 32,476,000 | 32,202,000 |
| Diluted Average Shares | 33,240,000 | -64,580,638 | 32,476,000 | 32,202,000 |
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)